2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

ASCO 2013 - Poster: Impact of concomitant bone-targeted therapies on outcomes in metastatic castration-resistant prostate cancer patients without prior chemotherapy treated with abiraterone acetate or prednisone

CHICAGO, IL USA (UroToday.com) - Presented by Fred Saad,1 Karim Fizazi,2 Matthew R. Smith,3 Thomas W. Griffin,4 Anil Londhe,5 Dana Rathkopf,6 Arturo Molina,4 Charles J. Ryan7 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 saad poster thumb

1University of Montréal, Montréal, Québec, Canada; 2Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 3Massachusetts General Hospital Cancer Center, Boston, MA; 4Janssen Research & Development, Los Angeles, CA; 5Janssen Research & Development, Raritan, NJ; 6Memorial Sloan-Kettering Cancer Center, New York, NY; 7Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA


Click HERE to listen to a podcast by Fred Saad, MD, FRCS, one of the participants in this study.

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

 

asco x

View Full ASCO 2013 Coverage